今日,Moderna 宣布其 mRNA 流感疫苗 mRNA-1010 在关键 3 期临床试验中取得重磅进展 —— 在针对 50 岁及以上成年人的研究中,该疫苗相对传统获批流感疫苗的效力提升 26.6%,标志着 mRNA 技术在流感预防领域的重大突破。这一成果不仅为 Moderna 叩开监管审批大门注入新动能,更推动其流感 / COVID 联合疫苗研发迈出关键一步。临床数据:全方位超越传统疫苗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.